{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:23:10Z","timestamp":1791994990994,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In Eswatini, multidrug-resistant (MDR)\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    (Mtb) strains harbouring the rifampicin-resistance (RR)\n                    <jats:italic>rpoB<\/jats:italic>\n                    I491F mutation are missed by routine diagnostics, including GeneXpert MTB\/RIF Ultra (Xpert Ultra), line probe assays (LPA), and mycobacterium growth indicator tube (MGIT) phenotypic drug susceptibility testing (pDST). To address this diagnostic gap, Eswatini introduced targeted next-generation sequencing (tNGS) in 2019. We analysed 234 patient samples enrolled from June 2021 to December 2024 with isoniazid and\/or rifampicin resistance detected by routine diagnostics, or suspected treatment failure, and obtained detailed clinical and outcome data from 59 patients. tNGS detected RR in 159 strains, of which 101 (64%) carried the\n                    <jats:italic>rpoB<\/jats:italic>\n                    I491F mutation. Bedaquiline (BDQ) resistance, conferred by\n                    <jats:italic>Rv0678<\/jats:italic>\n                    mutations, was identified in 87 strains, rendering 55% (87\/159) of RR and 85% (86\/101) of\n                    <jats:italic>rpoB<\/jats:italic>\n                    I491F strains genotypically BDQ-resistant. Routine tests substantially under-classified resistance, particularly in strains reported as isoniazid-resistant and rifampicin-susceptible. tNGS-informed treatment changes occurred in 53% (31\/59) of patients, with 88% (52\/59) treatment success. tNGS is therefore an essential tool to detect\n                    <jats:italic>rpoB<\/jats:italic>\n                    I491F \u201cdiagnostic escape\u201d strains with additional BDQ resistance, and underscores the urgent need to reconsider current BPaLM regimens and global drug-resistance classifications.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-73551-w","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:14:48Z","timestamp":1781133288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing"],"prefix":"10.1038","volume":"17","author":[{"given":"Debrah","family":"Vambe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangaliso","family":"Ziyane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mdigo","family":"Thunzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sein Sein","family":"Thi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"de Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-3693","authenticated-orcid":false,"given":"Viola","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busizwe","family":"Sibandze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijabu","family":"Masina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9727-6465","authenticated-orcid":false,"given":"Andrea Maurizio","family":"Cabibbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Furin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-8976","authenticated-orcid":false,"given":"Tafadzwa","family":"Mazuruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindokuhle","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thulani","family":"Jele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bheki","family":"Mamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gugu","family":"Maphalala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makhosazana","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mbongeni","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nomthandazo","family":"Lukhele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6415-1535","authenticated-orcid":false,"given":"Daniela Maria","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-3509","authenticated-orcid":false,"given":"Anna","family":"Mandalakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9691-4741","authenticated-orcid":false,"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sphiwe","family":"Ngwenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Utpatel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindisiwe","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6604-0684","authenticated-orcid":false,"given":"Stefan","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"73551_CR1","unstructured":"Global Tuberculosis Report 2025. Geneva: World Health Organization; 2025. Report."},{"key":"73551_CR2","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.5588\/ijtld.17.0230","volume":"21","author":"R Boyd","year":"2017","unstructured":"Boyd, R., Ford, N., Padgen, P. & Cox, H. Time to treatment for rifampicin-resistant tuberculosis: a systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 21, 1173\u20131180 (2017). Nov 1 PubMed PMID: 29037299; PubMed Central PMCID: PMC5644740.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"73551_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5588\/ijtldopen.25.0050","volume":"2","author":"J Boffa","year":"2025","unstructured":"Boffa, J. et al. TB elimination in Southern Africa: an overview and critical reflection. IJTLD Open 2, 381\u2013387 (2025). Jul PubMed PMID: 40657267; PubMed Central PMCID: PMC12248405.","journal-title":"IJTLD Open"},{"key":"73551_CR4","unstructured":"World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, 2nd Edition. 2023. Report."},{"key":"73551_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00793-8","volume":"12","author":"P Beckert","year":"2020","unstructured":"Beckert, P. et al. MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era. Genome Med. 12, 104 (2020). Nov 25.","journal-title":"Genome Med."},{"key":"73551_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMc1413930","volume":"372","author":"E Sanchez-Padilla","year":"2015","unstructured":"Sanchez-Padilla, E. et al. Detection of drug-resistant tuberculosis by Xpert MTB\/RIF in Swaziland. N. Engl. J. Med. 372, 1181\u20131182 (2015). Mar 19.","journal-title":"N. Engl. J. Med."},{"key":"73551_CR7","doi-asserted-by":"publisher","unstructured":"Barilar I., et al. Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB\/RIF in Mozambique: a retrospective observational study. Lancet Infect. Dis. 24, 297 (2023). S147330992300498X. https:\/\/doi.org\/10.1016\/S1473-3099(23)00498-X.","DOI":"10.1016\/S1473-3099(23)00498-X"},{"key":"73551_CR8","unstructured":"Sikhondze W. D. T. et al. XPERT MTB\/RIF misses more than 50% of rifampicin resistant tb cases in Eswatini: results of the 2ND national anti-tb drug resistance survey (2017\/2018)20191101_UNION2019_Abstracts_Final_0.pdf. In. The International Journal of Tuberculosis and Lung Disease. 2019. Available from: https:\/\/theunion.org\/\/sites\/default\/files\/2020-09\/20191101_UNION2019_Abstracts_Final_0.pdf"},{"key":"73551_CR9","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S1473-3099(22)00875-1","volume":"23","author":"J Dom\u00ednguez","year":"2023","unstructured":"Dom\u00ednguez, J. et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet\/RESIST-TB consensus statement. Lancet Infect. Dis. 23, e122\u2013e137 (2023). Apr.","journal-title":"Lancet Infect. Dis."},{"key":"73551_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1473-3099(21)00470-9","volume":"22","author":"NA Ismail","year":"2022","unstructured":"Ismail, N. A. et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect. Dis. 22, 496\u2013506 (2022). Apr PubMed PMID: 34780706.","journal-title":"Lancet Infect. Dis."},{"key":"73551_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36955-y","volume":"13","author":"J Snobre","year":"2023","unstructured":"Snobre, J. et al. Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678. Sci. Rep. 13, 10444 (2023). Jun 27 PubMed PMID: 37369740; PubMed Central PMCID: PMC10300004.","journal-title":"Sci. Rep."},{"key":"73551_CR12","doi-asserted-by":"publisher","first-page":"e964","DOI":"10.1016\/S2666-5247(23)00321-X","volume":"4","author":"C Lange","year":"2023","unstructured":"Lange, C., Vasiliu, A. & Mandalakas, A. M. Emerging bedaquiline-resistant tuberculosis. Lancet Microbe 4, e964\u2013e965 (2023). Dec 1 PubMed PMID: 37931639.","journal-title":"Lancet Microbe"},{"key":"73551_CR13","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S2666-5247(23)00002-2","volume":"4","author":"L Sonnenkalb","year":"2023","unstructured":"Sonnenkalb, L. et al. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis. Lancet Microbe 4, e358\u2013e368 (2023). May PubMed PMID: 37003285; PubMed Central PMCID: PMC10156607.","journal-title":"Lancet Microbe"},{"key":"73551_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1473-3099(23)00498-X","volume":"24","author":"I Barilar","year":"2024","unstructured":"Barilar, I. et al. Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB\/RIF in Mozambique: a retrospective observational study. Lancet Infect. Dis. 24, 297\u2013307 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"73551_CR15","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3201\/eid2911.230987","volume":"29","author":"C Modongo","year":"2023","unstructured":"Modongo, C. et al. Tuberculosis variant with Rifampin resistance undetectable by Xpert MTB\/RIF, Botswana. Emerg. Infect. Dis. 29, 2403\u20132406 (2023). Nov PubMed PMID: 37877680; PubMed Central PMCID: PMC10617350.","journal-title":"Emerg. Infect. Dis."},{"key":"73551_CR16","unstructured":"WHO consolidated guidelines on tuberculosis. Module 3: diagnosis\u2014rapid diagnostics for tuberculosis detection, third edition. Geneva: World Health Organization; 2024. Report."},{"key":"73551_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1056\/NEJMc2103049","volume":"386","author":"SV Omar","year":"2022","unstructured":"Omar, S. V., Ismail, F., Ndjeka, N., Kaniga, K. & Ismail, N. A. Bedaquiline-resistant tuberculosis associated with Rv0678 mutations. N. Engl. J. Med. 386, 93\u201394 (2022).","journal-title":"N. Engl. J. Med."},{"key":"73551_CR18","doi-asserted-by":"publisher","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","volume":"4","author":"B Derendinger","year":"2023","unstructured":"Derendinger, B. et al. Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study. Lancet Microbe 4, e972\u2013e982 (2023).","journal-title":"Lancet Microbe"},{"key":"73551_CR19","doi-asserted-by":"publisher","first-page":"e0002283","DOI":"10.1371\/journal.pgph.0002283","volume":"3","author":"J Timm","year":"2023","unstructured":"Timm, J. et al. Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid. PLOS Glob. Public Health 3, e0002283 (2023). Oct 18 PubMed PMID: 37851685; PubMed Central PMCID: PMC10584172.","journal-title":"PLOS Glob. Public Health"},{"key":"73551_CR20","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie, F. et al. Bedaquiline\u2013Pretomanid\u2013Linezolid regimens for drug-resistant tuberculosis. N. Engl. J. Med. 387, 810\u2013823 (2022). Sep 1 PubMed PMID: 36053506; PubMed Central PMCID: PMC9490302.","journal-title":"N. Engl. J. Med."},{"key":"73551_CR21","unstructured":"Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis,. Geneva: World Health Organization; October 2020. Report."},{"key":"73551_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1204064","volume":"11","author":"L de Araujo","year":"2023","unstructured":"de Araujo, L. et al. Implementation of targeted next-generation sequencing for the diagnosis of drug-resistant tuberculosis in low-resource settings: a programmatic model, challenges, and initial outcomes. Front Public Health 11, 1204064 (2023). PubMed PMID: 37674674; PubMed Central PMCID: PMC10478709.","journal-title":"Front Public Health"},{"key":"73551_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.103003","volume":"79","author":"S Shrestha","year":"2025","unstructured":"Shrestha, S., Addae, A., Miller, C., Ismail, N. & Zwerling, A. Cost-effectiveness of targeted next-generation sequencing (tNGS) for detection of tuberculosis drug resistance in India, South Africa and Georgia: a modeling analysis. EClinicalMedicine 79, 103003 (2025). Jan PubMed PMID: 39810935; PubMed Central PMCID: PMC11732181.","journal-title":"EClinicalMedicine"},{"key":"73551_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.01796-2020","volume":"57","author":"S Feuerriegel","year":"2021","unstructured":"Feuerriegel, S. et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur. Respir. J 57, 1 (2021). Jan.","journal-title":"Eur. Respir. J"},{"key":"73551_CR25","doi-asserted-by":"publisher","unstructured":"Jouet A., et al. Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs. Eur. Respir. J. 57, 2002338 (2020). Sep 17. https:\/\/doi.org\/10.1183\/13993003.02338-2020","DOI":"10.1183\/13993003.02338-2020"},{"key":"73551_CR26","doi-asserted-by":"publisher","unstructured":"Grobbel H. P., et al. Design of multidrug-resistant tuberculosis treatment regimens based on DNA sequencing. Clin. Infect. Dis. 73, 1194 (2021). Apr 26. https:\/\/doi.org\/10.1093\/cid\/ciab359","DOI":"10.1093\/cid\/ciab359"},{"key":"73551_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac042","volume":"4","author":"PM Mbelele","year":"2022","unstructured":"Mbelele, P. M. et al. Whole genome sequencing-based drug resistance predictions of multidrug-resistant Mycobacterium tuberculosis isolates from Tanzania. JAC Antimicrob. Resist. 4, dlac042 (2022). Apr PubMed PMID: 35465240; PubMed Central PMCID: PMC9021016.","journal-title":"JAC Antimicrob. Resist."},{"key":"73551_CR28","doi-asserted-by":"publisher","first-page":"e0128036","DOI":"10.1371\/journal.pone.0128036","volume":"10","author":"M Baym","year":"2015","unstructured":"Baym, M. et al. Inexpensive multiplexed library preparation for megabase-sized genomes. PLoS One 10, e0128036 (2015). PubMed PMID: 26000737; PubMed Central PMCID: PMC4441430.","journal-title":"PLoS One"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73551-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:03:46Z","timestamp":1786536226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73551-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73551"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73551-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M.M. has received honoraria from JANSSEN for participation in a data and safety monitoring board outside the scope of this work. C.L. has received speakers\u00b4 honoraria from Astra Zeneca, GSK, Gilead, Insmed, Jansen, MedUpdate and MedUpdateEurope and served on the WHO advisory board for target product profiles for novel TB regimens and on the WHO guideline development committee for the drug-resistant TB and is a scientific advisor for MSF for drug-resistant TB drug trials. All the other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8227"}}